Comparative Pharmacology
Head-to-head clinical analysis: ADDERALL XR 5 versus DAYTRANA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADDERALL XR 5 versus DAYTRANA.
ADDERALL XR 5 vs DAYTRANA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adderall XR 5 contains a combination of amphetamine and dextroamphetamine, which are central nervous system stimulants. They increase the levels of dopamine and norepinephrine in the synaptic cleft by inhibiting their reuptake and promoting their release from presynaptic neurons.
Methylphenidate is a central nervous system stimulant that blocks the reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their extracellular concentrations.
20 mg orally once daily in the morning
Initial: 10 mg transdermal patch applied to hip for 9 hours daily; may titrate weekly in increments of 5 mg to a maximum of 30 mg/day.
None Documented
None Documented
d-Amphetamine: 10-13 hours (adults), 11-14 hours (children); l-Amphetamine: 13-15 hours (adults). The prolonged terminal half-life of the extended-release formulation supports once-daily dosing.
Terminal half-life in children is approximately 5–6 hours; in adults, approximately 5 hours; wears off within 12 hours of patch removal.
Renal (approximately 90% as unchanged drug and metabolites, with 30-40% as unchanged amphetamine), fecal (minimal, <5%)
Renal (approx. 78% unchanged) and fecal (approx. 10%); remainder as metabolites.
Category C
Category C
CNS Stimulant
CNS Stimulant